Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3406]

Lenalidomide maintenance for transplant eligible and transplant ineligible...

Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK

Lenalidomide maintenance for transplant eligible and transplant ineligible newly diagnosed myeloma patients ( Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK )

Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in...

Dr Nadine Tung - Beth Israel Deaconess Medical Center, Boston, USA

Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA carriers with HER2-negative BC ( Dr Nadine Tung - Beth Israel Deaconess Medical Center, Boston, USA )

Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive...

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA

Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )

Oral paclitaxel with encequidar in metastatic breast cancer

Dr Gerardo Umanzor - Hospital del Valle, San Pedro Sula, Honduras

Oral paclitaxel with encequidar in metastatic breast cancer ( Dr Gerardo Umanzor - Hospital del Valle, San Pedro Sula, Honduras )

Breast cancer prevention in high-risk post-menopausal women

Prof Jack Cuzick - Queen Mary University of London, London, UK

Breast cancer prevention in high-risk post-menopausal women ( Prof Jack Cuzick - Queen Mary University of London, London, UK )

APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with...

Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium

APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with operable HER2-positive early breast cancer ( Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium )

Could trastuzumab deruxtecan become the new standard of care for pretreated...

Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA

Could trastuzumab deruxtecan become the new standard of care for pretreated HER2-positive breast cancer patients? ( Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA )

Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2...

Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium

Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2-positive breast cancer ( Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium )

Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer...

Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer patients pretreated with TDM-1 ( Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA )

Umbralisib, ublituximab and venetoclax in patients with relapsed or refractory...

Dr Paul Barr - Wilmot Cancer Institute, University of Rochester Medical Center

$Umbralisib, ublituximab and venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia ( Dr Paul Barr - Wilmot Cancer Institute, University of Rochester Medical Center )$

Myeloma highlights from ASH 2019

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

Myeloma highlights from ASH 2019 ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )

Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )

More from ecancer